Aldeyra Therapeutics Completes Phase 3 Trial Enrollment for Reproxalap
Company Announcements

Aldeyra Therapeutics Completes Phase 3 Trial Enrollment for Reproxalap

Aldeyra Therapeutics (ALDX) has provided an update.

Aldeyra Therapeutics, Inc. has successfully completed the enrollment for its Phase 3 clinical trial, which is investigating the efficacy of reproxalap, a potential new treatment for dry eye disease. This significant milestone in the drug’s development was announced through a press release and marks a crucial step forward in the company’s efforts to bring reproxalap to market for patients in need.

See more insights into ALDX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyAldeyra resubmits topical ocular reproxalap NDA to FDA
TheFlyBiotech Alert: Searches spiking for these stocks today
TipRanks Auto-Generated NewsdeskAldeyra Therapeutics Announces Executive Team Changes
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App